Evidence map›Paper›PMID 32961019›Full record

Observational studyClinical and translational science2021

Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.

Yosuke Suzuki, Yuri Sasamoto, Teruhide Koyama, Chisato Yoshijima, Masahiro Nakatochi, Michiaki Kubo, Yukihide Momozawa, Ritei Uehara, Keiko Ohno

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yosuke SuzukiDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan.
Yuri SasamotoDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan.
Teruhide KoyamaDepartment of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Chisato YoshijimaDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan.
Masahiro NakatochiDepartment of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Michiaki KuboLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Ritei UeharaDepartment of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Keiko OhnoDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan.
Meiji Pharmaceutical University · JPKyoto Prefectural University of Medicine · JPRIKEN Center for Integrative Medical Sciences · JPNagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coproporphyrin-I (CP-I) in plasma is a sensitive and specific endogenous probe for phenotyping organic anion transporting polypeptides 1B (OATP1B, encoded by SLCO1B). A few small-scale studies suggested that plasma CP-I concentration is affected by OATP1B1 polymorphism, but detailed studies are lacking. In this large-scale study, we measured plasma CP-I concentrations in 391 subjects from the Japanese general population, and evaluated the relationship between plasma CP-I concentrations and OATP1B1 polymorphisms to further assess the utility of plasma CP-I concentrations as an endogenous OATP1B probe. Plasma CP-I concentrations were 0.45 ± 0.12, 0.47 ± 0.16, 0.47 ± 0.20, 0.50 ± 0.15, 0.54 ± 0.14, and 0.74 ± 0.31 ng/mL in participants with OATP1B1*1b/*1b (n = 103), *1a/*1b (n = 122), *1a/*1a (n = 40), *1b/*15 (n = 74), *1a/*15 (n = 41), and *15/*15 (n = 11), respectively, showing an ascending rank order with significant difference (P < 0.0001). Post hoc analysis revealed significant increases in plasma CP-I concentration in OATP1B1*1b/*15 (P = 0.036), *1a/*15 (P = 0.0005), and *15/*15 (P = 0.0003) groups compared with the OATP1B1*1b/*1b group. There was no significant difference among OATP1B genotypes in plasma concentration of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a uremic toxin reported to decrease OATP1B activity in vivo. These findings confirm the utility of plasma CP-I concentrations as an endogenous biomarker for phenotyping of OATP1B activity. Plasma CP-I concentration is potentially useful for the study of drug-drug interactions via OATP1B or individual dose adjustment of OATP1B substrates.

Indexed as

AdultAgedAllelesBiomarkers, PharmacologicalCoproporphyrinsDose-Response Relationship, DrugDrug InteractionsFeasibility StudiesFemaleGenotyping TechniquesHumansJapanLiver-Specific Organic Anion Transporter 1MaleMiddle AgedPharmacogenomic VariantsBiomarkers, Pharmacologicalcoproporphyrin ICoproporphyrinsLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, human

Identifiers

PMID32961019
PMCPMC7877856
OpenAlexW3088659576

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.